Perspective Therapeutics, Inc.

Healthcare · Medical Devices · United States

Last price 1.15 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 131.27M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2...